The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy

Journal of Neuromuscular Diseases

Volumn 2, Issue 3, 2015, Pages 257-268

  Lowe, Jeovanna ^a,b   Wodarcyk, Andrew J ^a,b   Floyd, Kyle T ^a   Rastogi, Neha ^a   Schultz, Eric J ^a   Swager, Sarah A ^a,b   Chadwick, Jessica A ^a,b   Tran, Tam ^c   Raman, Subha V ^c   Janssen, Paul M L ^a   Rafael Fortney, Jill A ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

abdominal muscle; angiotensin converting enzyme inhibitors; diaphragm; Duchenne; dystrophin; heart; lisinopril; mdx; mineralocorticoid receptor antagonists; Muscular dystrophy; quadriceps muscle; utrophin; young mice

Indexed keywords

LISINOPRIL; MINERALOCORTICOID ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DIAPHRAGM; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DUCHENNE MUSCULAR DYSTROPHY; EXTENSOR DIGITORUM LONGUS MUSCLE; FEMALE; FUNCTIONAL STATUS; GRIP STRENGTH; HEART RATE; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MOUSE; MUSCLE CONTRACTION; MUSCLE INJURY; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; QUADRICEPS FEMORIS MUSCLE;

EID: 84992157303     PISSN: 22143599     EISSN: 22143602     Source Type: Journal    
DOI: 10.3233/JND-150099     Document Type: Article

References (18)

1. Emery AE, 2002 The muscular dystrophies. Lancet. 359 687 695
2. Verhaert D, Richards K, Rafael-Fortney JA, Raman SV, 2011 Cardiac involvement in patients with muscular dystrophies: Magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc Imaging 4 67 76
3. Cozzoli A, Nico B, Sblendorio VT, Capogrosso RF, Dinardo MM, Longo V, Gagliardi S, Montagnani M, De Luca A, 2011 Enalapril treatmentdiscloses an early role of angiotensin II in inflammation-andoxidative stress-related muscle damage in dystrophic mdx mice. Pharmacol Res 64 482 492
4. Rafael-Fortney JA, Chimanji NS, Schill KE, Martin CD, Murray JD, Ganguly R, Stangland JE, Tran T, Xu Y, Canan BD, Mays TA, Delfin DA, Janssen PM, Raman SV, 2011 Early treatment withlisinopril and spironolactone preserves cardiac and skeletalmuscle in duchenne muscular dystrophy mice. Circulation 124 582 588
5. Delyani JA, Rocha R, Cook CS, Tobert DS, Levin S, Roniker B, Workman DL, Sing YL, Whelihan B, 2001 Eplerenone: A selective aldosterone receptor antagonist (SARA). Cardiovascular Drug Reviews 19 185 200
6. Tamargo J, Solini A, Ruilope LM, 2014 Comparison of agents that affect aldosterone action. Seminars in Nephrology 34 285 306
7. Goemans N, Buyse G, 2014 Current treatment and management of dystrophinopathies. Current Treatment Options in Neurology 16 287
8. Raman SV, Hor KN, Mazur W, Halnon NJ, Kissel JT, He X, Tran T, Smart S, McCarthy B, Taylor MD, Jefferies JL, Rafael-Fortney JA, Lowe J, Roble SL, Cripe LH, 2015 Eplerenone for early cardiomyopathy inDuchenne muscular dystrophy: A randomised, double-blind, placebo-controlled trial. Lancet Neurol 14 153 161
9. van Putten M, Kumar D, Hulsker M, Hoogaars WM, Plomp JJ, vanOpstal A, van Iterson M, Admiraal P, van Ommen GJ, t Hoen PA, Aartsma-Rus A, 2012 Comparison of skeletal muscle pathology and motorfunction of dystrophin and utrophin deficient mouse strains. Neuromuscul Disord 22 406 417
10. Zhou L, Rafael-Fortney JA, Huang P, Zhao XS, Cheng G, Zhou X, Kaminski HJ, Liu L, Ransohoff RM, 2008 Haploinsufficiency of utrophin gene worsens skeletal muscleinflammation and fibrosis in mdx mice. J Neurol Sci 264 106 111
11. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM, Davies KE, 1997 Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90 717 727
12. Janssen PM, Murray JD, Schill KE, Rastogi N, Schultz EJ, Tran T, Raman SV, Rafael-Fortney JA, 2014 Prednisolone attenuates improvementof cardiac and skeletal contractile function and histopathology bylisinopril and spironolactone in the mdx mouse model of Duchennemuscular dystrophy. PLoS One 9 e88360
13. Elnakish MT, Schultz EJ, Gearinger RL, Saad NS, Rastogi N, Ahmed AA, Mohler PJ, Janssen PM, 2015 Differential involvement of varioussources of reactive oxygen species in thyroxin-induced hemodynamicchanges and contractile dysfunction of the heart and diaphragmmuscles. Free Radic Biol Med 83 252 261
14. Murray JD, Canan BD, Martin CD, Stangland JE, Rastogi N, Rafael-Fortney JA, Janssen PM, 2012 The force-Temperature relationship in healthy and dystrophic mouse diaphragm; implications for translational study design. Front Physiol 3 422
15. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS, 2004 Evolution of the mdx mouse cardiomyopathy: Physiological and morphological findings. Neuromuscul Disord 14 491 496
16. Morales MG, Cabrera D, Cespedes C, Vio CP, Vazquez Y, Brandan E, Cabello-Verrugio C, 2013 Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2). Cell and Tissue Research 353 173 187
17. Gardner BB, Swaggart KA, Kim G, Watson S, McNally EM, Cardiac function in muscular dystrophy associates with abdominal muscle pathology. Journal of Neuromuscular Diseases 2 39 49
18. Sali A, Guerron AD, Gordish-Dressman H, Spurney CF, Iantorno M, Hoffman EP, Nagaraju K, 2012 Glucocorticoid-Treated mice are an inappropriate positive control for long-Term preclinical studies in the mdx mouse. PLoS One 7 e34204